Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 6/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22627545 | 0.95 | TSPO (0.90) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL30849696 | 0.93 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL30849701 | 0.93 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL21191657 | 0.93 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL22345172 | 0.93 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL30849697 | 0.93 | TSPO (0.86) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL22612467 | 0.91 | TSPO (0.83) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL21191506 | 0.91 | TSPO (0.83) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL22612471 | 0.91 | TSPO (0.83) | TSPOGMNNLMNAPOLBCYP3A4 | |
| SCHEMBL10524649 | 0.90 | TSPO (0.82) | TSPOGMNNLMNAPOLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116599005-B | Secondary acceleration fault isolation method after direct current breaker failure | 天津大学 | 2024-08-20 | — | — | CN | claimed |
| US-20240251664-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-07-25 | — | — | US | claimed |
| CN-113078619-B | Rapid protection method for flexible direct-current power grid | 中国矿业大学 | 2022-07-15 | — | — | CN | claimed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | claimed |
| CN-122081225-A | Co-culture cell model of primary glial cells and neurons and culture method | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260143965-A1 | LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT | SAMSUNG DISPLAY CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| US-12550426-B2 | Semiconductor device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-02-10 | — | — | US | disclosed |
| US-12545024-B2 | Liquid discharge system | SEIKO EPSON CORPORATION (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20250340883-A1 | Method For Treating Cyclophilin B Associated Diseases | RESONANCE HEALTH ANALYSIS SERVICES PTY LTD (AU) | 2025-11-06 | — | — | US | disclosed |
| US-12437806-B2 | Semiconductor device and operating method thereof | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2025-10-07 | — | — | US | disclosed |
| US-12404293-B2 | Method for producing glycan, building block for gylican synthesis, and compound | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2025-09-02 | — | — | US | disclosed |
| US-12368388-B2 | Layout method for power supplies with three-phase integrated transformer and synchronous rectification | AA Power Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20160257739-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | ASCENDIS PHARMA A/S (DK) | 2016-09-08 | — | — | US | disclosed |
| EP-3054981-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | Ascendis Pharma A/S (DK) | 2016-08-17 | — | — | EP | disclosed |
| US-20150258205-A1 | Hydrogel Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2906617-A1 | HYDROGEL PRODRUGS | Ascendis Pharma A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015052155-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | ASCENDIS PHARMA A/S (DK) | 2015-04-16 | — | — | WO | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545024-B2 | Liquid discharge system | EXOSC9, EXOSC4, F5 | TSPO 4659/4885GMNN 1688/4885LMNA 3301/4885 |
| US-12550426-B2 | Semiconductor device | LASP1, MTREX, DCX | TSPO 3187/4885GMNN 2043/4885LMNA 4214/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | TSPO 3474/4885GMNN 2440/4885LMNA 3156/4885 |
| US-20160257739-A1 | PROTECTING GROUP COMPRISING A PURIFICATION TAG | GSTA2, GSTP1, MLN | TSPO 752/4885GMNN 873/4885LMNA 1768/4885 |
| US-12404293-B2 | Method for producing glycan, building block for gylican synthesis, and compound | OSTC, GYPA, AGL | TSPO 3711/4885GMNN 131/4885LMNA 1529/4885 |
| US-20150258205-A1 | Hydrogel Prodrugs | CD44, DNPH1, PHYKPL | TSPO 686/4885GMNN 888/4885LMNA 3876/4885 |
| US-20260143965-A1 | LIGHT EMITTING ELEMENT, AMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND DISPLAY DEVICE INCLUDING THE LIGHT EMITTING ELEMENT | NR2E3, NR2E1, NR0B2 | TSPO 4045/4885GMNN 3959/4885LMNA 1640/4885 |
| US-20240251664-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | NES, NFE2L2, NUCB2 | TSPO 2950/4885GMNN 815/4885LMNA 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.